Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press59610.36691/RJA596ArticlesСтатьиReview ArticlePHENOTYPES AND ENDOTYPES OF BRONCHIAL ASTHMA: FROM PATHOGENESIS AND CLINICAL FEATURES TO THERAPYФЕНОТИПЫ И ЭНДОТИПЫ БРОНХИАЛЬНОЙ АСТМЫ: ОТ ПАТОГЕНЕЗА И КЛИНИЧЕСКОЙ КАРТИНЫ К ВЫБОРУ ТЕРАПИИKurbachevaO MКурбачеваО МKurbacheva@gmail.comPavlovaK SПавловаК СInstitute of ImmunologyФГБУ «ГНЦ Институт иммунологии» ФМБА России15022013101NO1 (2013)№1 (2013)152410032020Copyright ©; 2013, Pharmarus Print MediaCopyright ©; 2013, Фармарус Принт Медиа2013Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/596

Questions of bronchial asthma heterogeneity, approaches to allocation of various phenotypes on the basis of clinical signs, biological and genetic markers and endotypes taking into account an etiology and pathophysiology of the disease are considered in the article. Allocation of phenotypes / endotypes promote the best understanding of essence of a disease and it is expedient for development of an individual approach to therapy as some options of a current OH can differ the resistant answer to standard treatment.

В статье рассмотрены вопросы гетерогенности бронхиальной астмы, подходы к выделению различных фенотипов на основании клинических признаков, биологических и генетических маркеров и эндотипов с учетом этиологии и патофизиологии заболевания. Выделение фенотипов/эндотипов способствует лучшему пониманию сущности заболевания и целесообразно для разработки индивидуального подхода к терапии, поскольку некоторые варианты течения БА могут характеризоваться резистентностью к стандартному лечению.

bronchial asthmaasthma phenotypesasthma endotypesinhaled corticosteroidsciclesonide (Alvesco)бронхиальная астмафенотипы астмыэндотипы астмыингаляционные глюкокортикостероидыциклесонид (Альвеско)Фрейдин М.Б., Пузырев В.П., Огородова Л.М. и соавт. Полиморфизм генов интерлейкинов и их рецепторов: популяционная распространенность и связь с атопической бронхиальной астмой. Генетика. 2002, т. 38, № 12, с. 1710-1718.Делягин В.М., Аракчеева Е.Е., Уразбагамбетов А., Будчанов Ю.И. Генетика бронхиальной астмы и атопии. Мед. совет. 2012, № 5, с. 33-39.Denham S., Koppelman G., Blakey J. et al. Meta-analysis of genome-wide linkage studies of asthma and related traits. Respir. Research. 2008, v. 9, No. 1, р. 1-38.Фрейдин М.Б., Огородова Л.М., Пузырев В.П. Вклад полиморфизма генов интерлейкинов в изменчивость количественных факторов риска атопической бронхиальной астмы. Мед. генетика. 2003, т. 2, № 3, с. 130-135.Mitsuyasu H., Izuhara K., Mao X.Q. et al. Ile50Val variants or IL4Ra upregulates IgE synthesis and associates with atopic asthma. Nat. genet. 1998, v. 19, р. 119-120.Wechsler M., Lehman E., Lazarus S. et al. National Heart, Lung and Blood Institute’s Asthma Clinical Research Network. beta-Adrenergic receptor polymorphisms and response to salmeterol. American Journal Respir. Crit. Care Medicine, 2006, v. 173, р. 519-526.Weaver C., Hatton R., Mangan P., Harrington L. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annual Revy Immunology. 2007, v. 25, p. 821-852.Bullens D., Truyen E., Coteur L. et al. IL-17 mRNA in sputum of asthmatic patients: linking T-cell driven inflammation and granulocytic influx? Respir. Res. 2006, v. 7, p. 135.Kawaguchi M., Takahashi D., Hizawa N. et al. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J. Allergy Clin. Immunol. 2006, v. 117, p. 795-801.Van Eerdewegh P., Little R., Dupuis J. et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002, v. 418, p. 426-430.Sleiman P., Flory J., Imielinski M. et al. Variants of DEN-ND1B associated with asthma in children. New England Journal of Medicine. 2010, v. 362, p. 36-44.Сардарян И.С. Фенотипические особенности бронхиальной астмы у детей при различных аллельных полиморфизмах генов «предрасположенности» (GSTT1, GSTМ1, ACE, eNOS). Автореферат диссертации канд. мед. наук. СПб. 2009, 22 с.Dehzad N., Bopp T., Reuter S. et al. Regulatory T-cells more effectively suppress Th1-induced airway inflammation compared with Th2. J. Immunol. 2011, v. 186, p. 238-2244.Schleich F.N., Seidel L., Sele J. et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma. Thorax. 2010, v. 65, p. 1039-1044.Gibson P.G. Inflammatory phenotypes in adult asthma: clinical applications. Clin. Respir. J. 2009, v. 3, p. 198-206.Wang F., He X.Y., Baines K.J. et al. Different inflammatory phenotypes in adults and children with acute asthma. Eur. Respir. J. 2011, v. 38, p. 567-574.Drews A.C., Pizzichini M.M., Pizzichini E. et al. Neutrophilic airway inflammation is a main feature of induced sputum in nonatopic asthmatic children. Allergy. 2009, v. 64, p. 1597-1601.Douwes J., Gibson P., Pekkanen J., Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax. 2002, v. 57, p. 643-648.Cosmi L., Liotta F., Maggi E., Romagnani S., Annunziato F. Th17-cells: new players in asthma pathogenesis. Allergy. 2011, v. 66, p. 989-998.Porsbjerg C., Lund T.K., Pedersen L., Backer V. Inflammatory subtypes in asthma are related to airway hyperresponsiveness to mannitol and exhaled NO. J Asthma. 2009, v. 46, p. 606-612.Lötval J., Akdis C.A., Bacharier L.B. et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J. Allergy Clin. Immunol. 2011, v. 127, p. 355-360.Ronmark E., Andersson C., Nystrom L. et al. Obesity increases the risk of incident asthma among adults. Eur. Respir. J. 2005, v. 25, p. 282-288.Shaaban R., Zureik M., Soussan D. et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008, v. 372, p. 1049-1057.Global Initiative for Asthma (GINA Report). Global Strategy for Asthma Management and Prevention. Update 2011. http://www.ginasthma.org/uploads/users/files/GINA_Re port2011_May4.pdfАллергология и иммунология: национальное руководство. Под ред. Р.М. Хаитова, Н.И. Ильиной. М., «ГЭОТАР-Медиа». 2009, 656 с.Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 3-е изд., испр. и доп. М., «Атмосфера». 2008, 108 с.Suissa S., Ernst P., Benayoun S. et al. Low-dose inhaled corticosteroids and prevention of death from asthma. N. Engl. J. Med. 2000, v. 343, No. 5, p. 332-336.Ненашева Н.М. Циклесонид (Альвеско®) — новый ингаляционный глюкокортикостероид для лечения бронхиальной астмы. Эффективная фармакотерапия. Пульмонология и оториноларингология. 2012, № 2, с. 22-34.Zhou J., Liu D.F., Liu C. et al. Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism. Allergy, 2008, v. 63 (9), p. 1177-1185Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус принт». 1998, 252 с.Derendorf H., Nave R., Drollman A. et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 2006, v. 28, No. 5, p. 1042-1050.Цой А.Н. Что определяет эффективность и безопасность применения ингаляционных ГКС в поддержании контроля над симптомами астмы. Справочник поликлинического врача. 2010, № 2, с. 37-43.Nave R., Meyer W., Fuhst R., Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm. Pharmacol. Ther. 2005, v. 18, p. 390-396.Winkler J., Hochhaus G., Derendorf H. How the lung handles drugs. Pharmacocinetics and pharmacodinamics of inchaled corticosteroids. Proc. Am. Thorac. Soc. 2004, v. 1, p. 356-363.Colice G.L. The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma. Expert. Opin. Pharmacother. 2006, v. 7, No. 15, p. 2107-2117.Rohatagi S., Appajosyula S., Derendorf H. et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J. Clin. Pharmacol. 2004, v. 44, No. 1, p. 37-47.Bousquet J. Introduction. Modulite: simplifying the changeover. Respir. Mad. 2002, v. 96, Suppl. D, S1-S2.Rohatagi S., Arya V., Zech K. et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J. Clin. Pharmacol. 2003, v. 43, p. 365-378.Bai T.R., Knight D.A. Structural changes in the airways in asthma: observations and consequences. Clin. Sci. (Lond.). 2005, v. 108, p. 463-477.Hamid Q., Song Y., Kotsimbos T.C. et al. Inflammation of small airways in asthma. J. Allergy Clin. Immunol. 1997, v. 100, 31, p. 44-51.De Vries T.W., Rottier B.L., Gjaltema D. et al. Comparative in vitro evaluation of four corticosteroid metered dose inhalers: Consistency of delivered dose and particle size distribution. Resp. Med. 2009, v. 103, No. 8, p. 1167-1173.Bateman E.D., Linnhof A.E., Homik L. et al. Comparison of twice daily inhaled ciclesonide and fluticasone propionate in patients with moderatetosevere persistent asthma. Pulm. Pharmacol Ther. 2008, v. 21, No. 2, p. 264275.Banerji D., Szwarcberg J., Fish J. et al. The incidence of oropharyngeal adverse events in adolescent/adults and pediatric. Asthma patients is similar for ciclesonide and placebo: results from pooled analyses. Allergy Asthma Proc. 2004, v. 25, p. 206.Bernstein J.A., Noonan M.J., Rim C. et al. Ciclesonide has minimal oropharyngeal side effects in the treatment of patients with moderate-to-severe asthma. J. Allergy Clin. Immunol. 2004, v. 113 (Suppl.), p. S113 [Abstract 349].Shapiro G., Bensch G., Lanier R. et al. Once-daily treatment with ciclesonide is effective and well-tolerated in children with persistent asthma [abstract]. J. Allergy Clin. Immunol. 2005, v. 115, S6.Agertoft L., Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J. Allergy Clin. Immunol. 2005, v. 115, p. 940-945.Skoner D.P., Maspero J., Banerji D. Ciclesonide Pediatric Growth Study Group. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics. 2008, v. 121, p. e1-e14.Chapman K.R., Patel P., Boulet L.P. et al. Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52 week long study. Eur. Respir. J. 2002, v. 20 (Suppl. 38), p. 373-374 [Abstract 2328].Lipworth B.J. Targets for inhaled treatment. Respir. Med. 2000, v. 94, Suppl. D., p. 13-16.Lindstroem M. Particles in small airways: mechanisms for deposition and clearance. Thesis, Stockholm: Karolinska Institute. 2004, 52 p.Schuepp K.G., Jauernig J., Janssens H.M. et al. In vitro determination of the optimal particle size for nebulised aerosol delivery to infants. J. Aerosol. Med. 2005, v. 18, No. 2, p. 225-235.